GET MORE AI-GENERATED SIGNALS: September 19, 2024, 20:16 pm ET, BY Jeff W.- Contributor| Editor: Thomas H. Kee Jr. ( Follow ...

British drugmaker GSK said on Wednesday it had agreed to settle two lawsuits in California that claimed its discontinued ...

Fulcrum Therapeutics (NASDAQ:FULC) announced Thursday after its lead program for protein kinase inhibitor losmapimod, in-licensed from GSK (GSK), failed ... to reach a new 52-week low as Wall ...

AL101 is an investigational human Announced new non-exclusive data license with GSK, introduced 23andMe Total Health™, and received FDA clearance for IND on novel, dual-mechanism immuno-oncology asset ...

British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot ...

A targeted immunotherapy being developed by iTeos Therapeutics and GSK, it was reported at #ESMO, delivered promising ...

GSK has revised its annual vaccine sales forecast following new guidance on RSV from the CDC. But new evidence offers new ...

GSK just settled another 2 (two) lawsuits in the UNITED STATES. And guess what folks AGAIN they admit ZERO LIABILITY. Now they have 76,998 lawsuits to go. Horrible MS EMMA allows the jury system ...

GSK has returned Wednesday morning with fresh phase 2 data that show new formulations of the vaccine “demonstrated positive A and B strain immune responses relative to standard of care in both ...

Miels said the new plan includes “changing our marketing mix to focus on segments who are tougher to activate.” Making Shields part of the marketing mix has enabled GSK to win mainstream media ...

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...